Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

This study has been terminated.
(Slow recruitment)
The Leukemia and Lymphoma Society
Information provided by:
Aegera Therapeutics Identifier:
First received: October 6, 2008
Last updated: July 12, 2011
Last verified: July 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)